



ΤΜΗΜΑ ΙΑΤΡΙΚΗΣ
Σχολή Επιστημών Υγείας
Πανεπιστήμιο Θεσσαλίας

UNIVERSITY OF THESSALY SCHOOL OF MEDICINE
LABORATORY OF BIOMATHEMATICS M.SC. "RESEARCH
METHODOLOGY IN BIOMEDICINE, BIOSTATISTICS AND
CLINICAL BIOINFORMATICS

MASTER THESIS

**«A protocol for an observational study for telmisartan in the treatment
of patients with hypertension »**

FOYSIKA MARIANTHI

Committee members:

Prof. Stefanidis Ioannis

Prof. Zintzaras Elias

Prof. Hadjigeorgiou Georgios

LARISSA, SEPTEMBER, 2016

TABLE OF CONTENTS

1 ABSTRACT	3
1.1 Background	3
1.2 Aims	3
1.3 Materials and Methods.....	3
1.4 Results.....	3
1.5 Conclusion.....	3
2 INTRODUCTION	4
3 BIBLIOGRAPHY	12

A protocol for an observational study for telmisartan in the treatment of patients with hypertension

ABSTRACT

Background: Telmisartan has effective treatment of hypertension in a broad spectrum of hypertensive patients offering the advantage of very long half-life and enables blood pressure control over 24 hours using once-daily administration.

Aims: To evaluate the efficacy of telmisartan in daily clinical practice and to assess whether or not telmisartan elicits beneficial effects on the progression of microalbuminuria in normotensive and hypertensive patients.

Setting and Design: Observational 4-week clinical study

Materials and Methods: Hypertensive and normotensive outpatients with type 2 diabetes and microalbuminuria were started on telmisartan 40 mg/day with optional up-titration to 80 mg/day in order to achieve seated systolic (SSBP) and diastolic (SDBP) blood pressure <140/90 mm Hg. Intent-to-treat and per protocol efficacy assessment was based on SSBP/SDBP reduction and delivered doses.

Results: SSBP/SDBP was decreased and patients showed lower transition rates from microalbuminuria to overt nephropathy compared to the placebo group. In normotensive patients treated with telmisartan, changes in urinary albumin-to-creatinine were not significantly correlated with changes in blood pressure. The present study demonstrates that telmisartan prevents the progression of microalbuminuria in normotensive patients with type 2 diabetes.

Conclusion: Telmisartan is shown to be safe and well tolerated in these patients.

INTRODUCTION

Hypertension (HT) is a well-established risk factor responsible for cardiovascular disease (CVD) and chronic kidney disease (CKD). High blood pressure (BP) is associated with development of CVD in a continuous manner; risk increases with incremental BP, even within the normal range. Hypertension is one of the main causes of death worldwide and has emerged as increasingly important medical and public health issue. It affects approximately 25% of the adult population worldwide, and its prevalence is predicted to approach the 60% by 2025 (Keamay et al., 2005) It is considered as a treatable risk factor for:

- coronary heart disease (CHD) ,
- congestive heart failure (CHF),
- ischemic
- haemorrhagic stroke ,
- renal failure
- peripheral arterial disease (PAD)

According to the Seventh Report of the Joint National Committee (JNC-7) on prevention, detection, evaluation and treatment of high blood pressure, systolic blood pressure (SBP) > 140 mmHg is a crucial risk factor for CVD than diastolic blood pressure (DBP) in subjects of > 50 years old. Clinical trials and observational studies suggest that poor systolic blood pressure control is largely responsible for the unacceptably low rates of overall blood pressure control. Systolic blood pressure control rates appeared less of 60–70% while diastolic blood pressure control rates exceeded 90% in the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial, and Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (Jones et al., 2000; Cushman et al.,2002; Midha et al., 2010; Black et al., 2001; Weir, 1998).

Patients with hypertension often present glucose tolerance with hypertension and diabetes mellitus and at the same time the symptomatology include also renal failure, early development of cardiovascular disease, and premature death. (Go et al., 2004). Kidney is a vital target organ in both hypertension and diabetes, with late studies uncovering that microalbuminuria is an early clinical marker of nephropathy, as well as a crucial indicator of cardiovascular occasions in both nondiabetic and diabetic population .Particular efforts are made to diminish urinary albumin excretion as the danger of cardiovascular morbidity and mortality increases with expanding urinary excretion of albumin with no conspicuous threshold or plateau (Manolis et al.,2004).

Numerous patients with fundamental hypertension may give clear or sub-clinical target organ damage (TOD) including heart, kidneys, central nervous system or retina at the season of their underlying analysis (Cuspidi et al., 2004). The assessment of sub-clinical TOD has turned into the key component in assessing hypertensive patients. Microalbuminuria (MA) is connected with high rate of morbidity expressing a condition of expanded renal endothelial dysfunction and is viewed as an early marker of diffuse endothelial permeability. Since reducing albuminuria delays the progression of the dysfunctions , this parameter can be utilized for measuring the adequacy of the various therapies.

In the course of the most recent couple of decades, the Renin Angiotensin system (RAS) has been a medication focused on cardiovascular and renovascular diseases. The two classes of medications that target the RAS are the Angiotensin converting enzyme (ACE) inhibitors and the specific AT1 receptor blockers (ARBs). Both ACE inhibitors and ARBs are powerful antihypertensive drugs that have been appeared to reduce the danger of cardiovascular and renal dysfunctions (O'Hare et al., 2000).

Angiotensin II receptor blockers (ARBs) are powerful antihypertensive drugs and are broadly viewed as having tolerability profiles like that of placebo. (Lacourciere et al., 2003) Of the available ARBs, Telmisartan has the longest half-life of around 24 h (Lefebvre et al., 2002) This proposes Telmisartan ought to have a long throughout the once-daily dosing interval. Another component recognizing Telmisartan from different ARBs is its high lipophilicity. (Littlejohn et al., 2002) This improves tissue penetration, intracellular absorption and bioavailability. The high lipophilicity of Telmisartan, in correlation with losartan, may give vascular protection (Mallion et al., 1999)

Another component that recognizes Telmisartan from the ARBs candesartan, Cilexetil, losartan, is that it is not a prodrug; consequently antihypertensive intensity is related to the activity of the parent compound (Nishimura et al., 2005). Most studies are of short duration, with one and only long term investigation of 1-year span. The suggested beginning dose of Telmisartan for the vast majority with hypertension is 40 mg once every day. Taking into account the pulse reaction and/or Telmisartan symptoms, the dosage might be expanded or diminished. With every adjustment in dosage, it might take a few weeks to see the full impact of Telmisartan on bringing down pulse. The suggested dose of Telmisartan for reducing the danger of cardiovascular issues, in individuals at high risk for such issues is 80 mg every day (Markham et al., 1997).

The issue of masked hypertension can be exacerbated in people getting treatment for hypertension, in light of the fact that numerous antihypertensive medications have an impact at trough that is significantly lower than their peak effect. In fact, in the 1990s when most currently utilized antihypertensives were assessed, the US Food and Drug Administration's measure for a powerful antihypertensive drug was one with a through-peak ratio of no less than 50% (Meredith and Elliott, 1994).

Therapeutic methodologies to moderate declining kidney work and to avert cardiovascular events ought to go for both large reductions in blood

pressure (BP) and diminished renal albumin excretion (Neutel et al., 2003). Angiotensin receptor blockers (ARBs) have protective effects on kidney in patients with diabetic nephropathy, but monotherapy with a standard dose of ARB is frequently inadequate to accomplish the suggested BP goals (Nalbantgil et al., 2004; White et al., 2004; Sharm et al., 2007)

A reasonable examination among different antihypertensive specialists can't be built up exclusively on the premise of trough–pinnacle proportions (Lefebvre et al 2002). Since the drug is typically directed once every day and taken in the morning to support persistent consistence, peak efficacy is likely to happen around the time of morning blood pressure estimation in the doctor's office. By complexity, the trough impact may agree with the early morning time frame towards the end of the dosing interim. Therefore, patients with treated hypertension regularly have generally higher morning blood pressure contrasted and office blood pressure. (Redon et al 2002).

Clinical guidelines have suggested threshold levels for the usage of antihypertensive treatment, normally taking into account blood pressure levels (Chobanian et al 2003; Guidelines Committee 2003; Whitworth 2003). Angiotensin II receptor blockers (ARBs) are profoundly powerful antihypertensive drugs and are generally viewed as having great tolerability (Meredith 2005). Of the commercially available ARBs, telmisartan has the longest half-life of about 24 h (Burnier and Maillard 2001; Brunner 2002). Telmisartan, is a long-acting angiotensin receptor blocker (ARB), having therapeutic effects that go beyond blood pressure control, as a non-peptide AT1 receptor antagonist, orally active, highly selective, potent (Burnier, Maillard 2001; Brunner 2002; Wiene et al 2000).

Among the class of AT1 receptor antagonist, telmisartan offers the advantage of very long half-life. Telmisartan ought to have a long activity, in this way guaranteeing blood pressure control all through the once-day by day dosing interval. Another component recognizing telmisartan from different

Angiotensin II receptor blockers is the fact that presents high lipophilicity conferring vascular protection (Wienen et al 2000; Takai et al 2005). This fact increase, also, its penetration on various tissues, its intracellular absorption and bioavailability, reflecting in the high volume of distribution of approximately 500L (Stangier et al 2000). Another feature is that it is not a prodrug and as a consequence antihypertensive potency is related to the activity of the parent compound (Wienen et al 2000; Stangier et al 2000).

The hypertensive and normotensive people display a comparative circadian variation in blood pressure, levels being high at the daytime and low in the middle of the night (Staessen et al 1997; Elliot et al., 1998). On arousing, the blood pressure surges, however the degree of this surge can change in various people with some showing morning hypertension (Gosse et al 2004). In different subjects, blood pressure is increased at the evening time and hypertension holds on in the morning. An immediate connection exists between SBP on arising and left ventricular mass (Gosse et al 1997), and the SBP on emerging has been appeared to be rather higher in the subjects who have cardiovascular complications (Gosse et al 2001, 2004). Multivariate examination found that the relationship between early morning blood pressure and cardiovascular risk was autonomous of age and 24 h circulatory strain. A relationship has been shown between a high early morning blood pressure surge and microalbuminuria (Polonia et al 2005).

Also various studies have observed that treatment with ARBs or ACEIs results in long-term stabilization or standardization of albuminuria in normotensive type 2 diabetic patients. In any case, no complete largescale study has researched regardless of whether angiotensin blockade prevents the progression of albuminuria in normotensive patients with type 2 diabetes. This examination ought to be especially essential since it has been revealed that Japanese diabetic patients are substantially more powerless than Caucasians to end-stage renal disease (Hirose, 2005). It was recently observed that the Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study to

analyze the impact of telmisartan, an ARB, on the progression of microalbuminuria in Japanese patients with type 2 diabetes . This study included 163 normotensive and 351 hypertensive patients. The significant finding was that telmisartan treatment adequately reduced the transition rate from incipient to obvious nephropathy in Japanese type 2 diabetic patients (Viberti et al., 2002; Wachtell et al., 2003).

Data collected in various European and Non European Countries, together with the BP values reported in large-scale intervention trials, demonstrate that at the best close to 25–30% of treated hypertensive patients display during treatment BP values beneath 140/90 mmHg and that these figures are worse in diabetic or nephropathic hypertensive patients, in which BP objectives are, as indicated by the suggestions of late European Guidelines, < 130/80 mmHg. Also other studies have shown that the extent of patients with controlled BP has been appeared to be low in patients with a cardiovascular risk profile (past myocardial localized necrosis, diabetes, metabolic disorder, renal deficiency), which by definition would require more noteworthy cardioprotection. Recently, some change in BP control has been accounted for, especially in England. Also BP control is similarly poor when evaluated through the sphygmomanometric system or via semi-automatic or ambulatory BP monitoring (ABPM) method (Mallion et al., 1999; Clemente et al., 2003)

The main features of an ideal antihypertensive agent. Are

- Greater blood pressure lowering effects
- Better blood pressure control
- Balanced action throughout 24 hours
- Greater cardiovascular protection (brain, heart and kidney)
- Efficacy in a broad range of subjects
- Tolerability profile at least comparable to existing agents
- Properties to enhance patient's compliance
- Sympathomodulatory and cardioprotective properties

- Neutral or favorable metabolic effects
- Evidence for long-term benefits
- Potential utility across cardiovascular continuum of responders increases with increasing daily drug dosage up to 40–80 mg/day and ranges from 69–81%.

(Williams et al., 2009)

The % of treated patients achieving a target sitting DBP < 90 mmHg (i.e. the normalisation rate) also increases with the dosage, at the 80 mg daily dose amounting to about 64–84%.^{1,10}

One randomised, double-blind multicentre study evaluated long-term telmisartan administration in patients with isolated systolic hypertension, showing in more than 50% of the treated hypertensives a target reduction in SBP, defined as a systolic value < 140 mmHg or a decrease of > 20 mmHg. (Neutel, 2003;2005). These figures have been confirmed by a number of studies performed by employing 24-hour ABPM, which additionally documented both in uncomplicated and complicated hypertension (renal insufficiency, renal failure, diabetes mellitus, obesity as well as metabolic syndrome) that

- 1) the drug effectively reduces BP values throughout the 24-hour average interval,
- 2) the antihypertensive effect follows the circadian rhythm of BP, allowing protection of the cardiovascular system against the early morning BP rise and its adverse effects on the heart and vital organs(Cohen, 1997).

A growing body of evidence indicates that renoprotective effects of ARBs and ACEIs not only in hypertensive exist also in normotensive diabetic patients. The ACE-Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects (ATLANTIS) study demonstrated that treatment with ramipril had no effect on glomerular filtration rate, but significantly

decreased microalbuminuria in normotensive type 1 diabetic patients. Similarly, captopril significantly decreased albuminuria in normotensive type 1 diabetic patients with albuminuria >300 mg/d. Further study showed that an ARB—losartan, irbesartan, or valsartan —significantly decreased urinary albumin excretion in normotensive type 2 diabetes.(Teo et al., 2004)

A comparison of telmisartan versus losartan in hypertensive type 2 Diabetic patients with overt nephropathy (AMADEO) – was designed to determine whether pharmacological differences between telmisartan and losartan would translate into larger and more durable reductions in proteinuria over time. Compared with losartan (an ARB already approved for diabetic nephropathy to prevent renal disease progression), (Zandbergen et al., 2003), the highly lipophilic ARB telmisartan has a longer half-life and displays approximately 25% greater angiotensin II type 1 receptor binding (Burnier,2001).

The multicenter, double-blind, prospective study was performed in 860 hypertensive (SBP/DBP >130/ 80 mmHg or receiving antihypertensive medication at baseline) patients with type 2 diabetes and who had a morning spot urinary protein-to-creatinine ratio 700 mg/g or more. After a placebo run-in period, the randomized patients received either telmisartan 40 mg or losartan 50 mg for 2 weeks, followed by telmisartan 80 mg or losartan 100 mg, respectively, for 50 weeks. The magnitude of the reduction in proteinuria expressed as UACR at 52 weeks – the primary endpoint – was significantly greater with telmisartan (29.8%) compared with losartan (21.4%; $P = 0.027$) (Bakris et al., 2008).

Recent evidence describe that it is not just hard to accomplish sphygmomanometric (or center) BP control additionally to extend this control to different parameters, (for example, home BP) which assume a noteworthy part in deciding the long term risk of fatal and nonfatal cardiovascular events. Finally, data gathered with regards to the European Lacidipine Study on Atherosclerosis have demonstrated that it is difficult to accomplish as well as to keep up a BP control in the long term period. The antihypertensive efficacy

of telmisartan (20–160 mg/day) and its capacity to accomplish satisfied BP control have been all around recorded in randomized, multicentre studies about, the treatment length with a duration of 4–52 weeks. The antihypertensive impact of the medication is generously present within 1–2 weeks of starting treatment, accomplishing a plateau after 8–10 weeks and being from that point well maintained

At the present study we plan to evaluate the efficacy of telmisartan in daily clinical practice and to assess whether or not telmisartan elicits beneficial effects on the progression of microalbuminuria in normotensive and hypertensive patients. The study will have a duration of 4-week observation of the patients.

The sample will be hypertensive and normotensive outpatients with type 2 diabetes and microalbuminuria starting telmisartan 40 mg/day with optional up-titration to 80 mg/day in order to achieve seated systolic (SSBP) and diastolic (SDBP) blood pressure <140/90 mm Hg. Intent-to-treat and per protocol efficacy assessment was based on SSBP/SDBP reduction and delivered doses

BIBLIOGRAPHY

1. Bakris G, Burgess E, Weir M, Davidai G, Koval S. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. *Kidney Int* 2008; 74:364–369.
2. Bakris GL, Weir MR, Shanifar S, et al: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. *Arch Intern Med* 2003; 163: 1555–1565.
3. Basile J. 2002. Hypertension in the elderly: a review of the importance of systolic blood pressure elevation. *J Clin Hypertens*, 4:108-12.

4. Bjorklund K, Lind L, Zethelius B, et al. 2003. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. *Circulation*, 107:1297-302.
5. Bobrie G, Chatellier G, Genes N, et al. 2004. Cardiovascular prognosis of masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. *JAMA*, 291:1342-9.
6. Brunner HR. 2002. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. *J Hum Hypertens*, 16(Suppl 2):S13-16.
7. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. *J Hum Hypertens*. 2002;16(Suppl 2):S13–16.
8. Burnier M, Maillard M. 2001. The comparative pharmacology of angiotensin II receptor antagonists. *Blood Press*, 10(Suppl 1):6-11.
9. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. *Blood Press*. 2001;10(1):6–11.
10. Burnier M. Angiotensin II type 1 receptor blockers. *Circulation* 2001; 103:904–912
11. Buse JB, Ginsberg HN, Bakris GL, et al: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Circulation* 2007; 115: 114–126.
12. Casas JP, Chua W, Loukogeorgakis S, et al: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *Lancet* 2005; 366: 2026–2033.
13. Chandie Shaw PK, Baboe F, van Es LA, et al: South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients. *Diabetes Care* 2006; 29: 1383–1385.

14. Chobanian AV, Bakris GL, Black HR, et al. 2003. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *JAMA*, 289:2560-72.
15. Clement DL, De Buyzere ML, De Bacquer DA, et al. 2003. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. *N Engl J Med*, 348:2407-15.
16. Cohen MC. 1997. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. *Am J Cardiol*, 79:1512-16.
17. Cuspidi C, Meani S, Fusi V, et al. 2004. Metabolic syndrome and target organ damage in untreated essential hypertensives. *J Hypertens*, 22:1991-8.
18. Elliott WJ. 1998. Circadian variation in the timing of stroke onset: a metaanalysis. *Stroke*, 29:992-6.
19. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. *Vasc Med* 2002; 7:35–43.
20. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004; 351:1296–1305.
21. Gosse P, Ansoborlo P, Lemetayer P, et al. 1997. Left ventricular mass is better correlated with arising blood pressure than with office or occasional blood pressure. *Am J Hypertens*, 10:505-10.
22. Gosse P, Cipriano C, Bemurat L, et al. 2001. Prognostic significance of blood pressure measured on rising. *J Hum Hypertens*, 15:413-17.
23. Gosse P, Lasserre R, Minifie C, et al. 2004. Blood pressure surge on rising. *J Hypertens*, 22:1113-18.
24. Gosse P, Neutel JM, Schumacher H, et al. 2005. Reduction of early morning blood pressure surge with telmisartan compared with ramipril in mild to-moderate hypertensive patients. *J Hypertens*, 23(Suppl 2):S375-6.
25. Grimm RH Jr, Svendsen KH, Kasiske B, Keane WF, Wahi MM. Proteinuria is a risk factor for mortality over 10 years of follow-up.

- MRFIT Research Group. Multiple Risk Factor Intervention Trial. *Kidney Int Suppl* 1997; 63:S10–14.
26. Guidelines Committee. 2003. European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens*, 21:1011-53.
 27. Heyden S, Schneider KA. 1990. Obesity and hypertension: epidemiological aspects of the relationship. *J Hum Hypertens*, 4:431-5.
 28. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al., Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation* 2002; 106:1777–1782.
 29. Hirose T, Kawamori R: Diabetes in Japan. *Curr Diab Rep* 2005; 5: 226–229.
 30. Hollenberg NK: Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. *Curr Hypertens Rep* 2001; 3: 177.
 31. Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). *Hypertens Res* 2006; 29 (Suppl): S1– S105.
 32. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. *Hypertension* 2000; 35:898–903.
 33. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. *Am Heart J* 1984; 108:1347–1352.
 34. Kario K, Pickering TG, Umeda Y, et al. 2003. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation*, 107:1401- 6.
 35. Kearney PM, Whelton M, Reynolds K, et al. 2004. Worldwide prevalence of hypertension: a systematic review. *J Hypertens*, 22:11-19.

36. Khan NA, McAlister FA, Rabkin SW, et al: The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II—Therapy. *Can J Cardiol* 2006; 22: 583–593.
37. Lacourcière Y, Gil-Extremera B, Mueller O, et al. 2003. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. *Int J Clin Pract*, 57:273-9.
38. Lacourcière Y, Krzesinski JM, White WB, et al. 2004a. Sustained antihypertensive activity of telmisartan compared with valsartan. *Blood Press Monit*, 9:203-10.
39. Lacourcière Y, Lenis J, Orchard R, et al. 1998. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. *Blood Press Monit*, 3:295-302.
40. Lacourcière Y, Neutel J, Davidai G, et al. 2006. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. *Am J Hypertens*, 19:104-12.
41. Lacourcière Y, Neutel J, Koval SE, et al. 2004b. A prospective, randomized investigation of the safety and efficacy of telmisartan vs ramipril in mild-to-moderate hypertensives using ambulatory blood pressure monitoring. *Hypertension*, 44:576.
42. Lefebvre J, Poirier L, Lacourcière Y. 2002. Methodology to determine duration of action for antihypertensive drugs. *Ann Pharmacother*, 36:874-81.
43. Lewington S, Clarke R, Qizilbash N, et al. 2002. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*, 360:1903-13.
44. Littlejohn T, Mroczek W, Marbury T, et al. 2000. A prospective, randomized, open-label trial comparing telmisartan 80 mg and valsartan

- 80 mg in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. *Can J Cardiol*, 16:1123-32.
46. Makino H, Haneda M, Babazono T, et al: Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. *Diabetes Care* 2007; 30: 1577–1578. 2
47. Makino H, Haneda M, Babazono T, et al: The telmisartan renoprotective study from incipient nephropathy to overt nephropathy—rationale, study design, treatment plan and baseline characteristics of the Incipient to Overt: Angiotensin II Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. *J Int Med Res* 2005; 33: 677–686.
48. Mallion JM; Siché JP, Lacourcière Y, et al. 1999. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. *J Hum Hypertens*, 13:657-64.
49. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2007; 25:1105–1187.
50. Manolis AJ, Reid JL, de Zeeuw D et al. Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo. *J Hypertens* 2004;22:1033-7.
51. Markham A, Goa KL. 1997. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. *Drugs*, 54:299-311.
52. Marler JR, Price TR, Clark GL, et al. 1989. Morning increase in onset of ischemic stroke. *Stroke*, 20:473-6.

53. Meredith PA, Elliott HL. 1994. FDA guidelines on trough: peak ratios in the evaluation of antihypertensive agents. United States Food and Drug Administration. *J Cardiovasc Pharmacol*, 23(Suppl 5):S26-30.
54. Meredith PA. 2005. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. *Am J Cardiovasc Drugs*, 5:171-83.
55. Meredith PA. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. *Am J Cardiovasc Drugs*. 2005; 5:171–83.
56. Motwani JG. 2002. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. *J ReninAngiotensin Aldosterone Syst*, 3:72-8.
57. Muller JE, Stone PH, Turi ZG, et al. 1985. Circadian variation in the frequency of onset of acute myocardial infarction. *N Engl J Med*, 313:1315-22.
58. Nalbantgil I, Nalbantgil S, Ozerkan F et al. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension. *Int J Clin Pract Suppl* 2004;145:50-4.
59. Neldam S; for the ATHOS Group. 2005. Telmisartan + hydrochlorothiazide versus amlodipine + hydrochlorothiazide in older patients with predominantly systolic hypertension. *J Hypertens*, 23(Suppl 2):S116.
60. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. *J Clin Hypertens (Greenwich)* 2003; 5:58-63.
61. Neutel JM, Littlejohn TW, Chrysant SGSA, et al. 2005. Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. *Hypertens Res*, 28:555-63.
62. Nishimura T, Hashimoto J, Ohkubo T, et al. 2005. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients

- with essential hypertension determined by home blood pressure measurements. *Clin Exp Hypertens*, 27:477-89.
63. O'Hare P, Bilbous R, Mitchell T, O'Callaghan CJ, Viberti GC, ACE-Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects Study Group: Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. *Diabetes Care* 2000; 23: 1823–1829.
64. Parati G, Lantelme P. 2002. Blood pressure. *J Hypertens*, 20:1725-9.
65. Parving HH, Hommel E, Jensen BR, Hansen HP: Longterm beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. *Kidney Int* 2001; 60: 228–234.
66. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG, DEMAND investigators: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. *Kidney Int* 2006; 69: 2057– 2063.
67. Pickering TG, Davidson K, Gerin W, et al. 2002. Masked hypertension. *Hypertension*, 40:795–6.
68. Pierdomenico SD, Lapenna D, Bucci A, et al. 2005. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. *Am J Hypertens*, 18:1422-8.
69. Polonia J, Amado P, Barbosa L, et al. 2005. Morning rise, morning surge and daytime variability of blood pressure and cardiovascular target organ damage. A cross-sectional study in 743 subjects. *Rev Port Cardiol*, 24:65-78.
70. Prasad P, Tiwari AK, Kumar KM, et al: Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. *BMC Med Genet* 2006; 7: 42.
71. Rahmouni K, Correia ML, Haynes WG, et al. 2005. Obesity-associated hypertension: new insights into mechanisms. *Hypertension*, 45:9-14.
72. Redon J, Rocha-Cusachs A, Mora-Macia J. 2002. Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study. *Blood Press Monit*, 7:111-16.

73. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culeton B, Hamm LL, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation* 2003; 108:2154– 2169.
74. Sasso FC, Carbonara O, Persico M, et al: Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. *Diabetes Care* 2002; 25: 1909–1913.
75. Sharma AM, Davidson J, Koval S, Lacourciere Y. Telmisartan/hydrochlorothiazide vs. valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. *Cardiovasc Diabetol* 2007;6:28
76. Sharma AM, Davidson JA, Gavin JR III, et al. 2005. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes European Council for Cardiovascular Research Presented at the 10th Annual Meeting of the European Council for Cardiovascular Research (ECCR), 14–16 October 2005, Nice, France.
77. Smith DH, Neutel JM, Lacourcière Y, et al. 2003. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. *J Hypertens*, 21:1291-8.
78. Staessen JA, Bieniaszewski L, O'Brien E, et al. 1997. Nocturnal blood pressure fall on ambulatory monitoring in a large international database. *Hypertension*, 29:30-9.
79. Staessen JA, Li Y, Thijs L, et al. 2005. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. *Hypertens Res*, 28:385-407.

80. Stangier J, Su C-APF, Roth W. 2000. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. *J Int Med Res*, 28:149-67.
81. Takai S, Kirimura K, Jin D, et al. 2005. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. *Hypertens Res*, 28:593-600.
82. Takai S, Kirimura K, Jin D, et al. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. *Hypertens Res*. 2005; 28:593–600.
83. Teo K, Yusuf S, Anderson C, et al. 2004. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. (ONTARGET/TRANSCEND) trials. *Am Heart J*, 148:52-61.
84. Verdecchia P, Angeli F. 2004. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. *Clin Ther*, 26:460-72.
85. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation* 2002; 106: 672–678.
86. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Ann Intern Med* 2003; 139:901–906.
87. Weir MR. 1998. The rationale for combination versus single-entity therapy in hypertension. *Am J Hypertens*, 11(Suppl 10):163S-9S.
88. White WB, Lacourcière Y, Davidai G. 2004. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. *Am J Hypertens*, 17:347-53.

89. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan vs. valsartan on the circadian variation of blood pressure: impact on the early morning period. *Am J Hypertens* 2004;17:347-53.
90. White WB, Weber MA, Davidai G, et al. 2005. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. *Blood Press Monit*, 10:157-63.
91. Whitworth JA. 2003. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*, 21:1983-92.
92. Wienen W, Entzeroth M, van Meel JCA, et al. 2000. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. *Cardiovasc Drug Rev*, 18:127-56.
93. Wienen W, Entzeroth M, van Meel JCA, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. *Cardiovasc Drug Rev*. 2000;18:127–56.
94. Williams B, Gosse P, Lowe L, et al. 2006. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). *J Hypertens*, 24:193-200.
95. Williams B, Lacourcière Y, Schumacher H, et al. 2005. Telmisartan versus ramipril in 24-h ambulatory blood pressure: a pooled analysis of 2 prospective, randomized trials in mild-to-moderate hypertensive patients [abstract]. *J Hypertens*, 23(Suppl 2):S381, P3.372.
96. Willich SN, Goldberg RJ, Maclure M, et al. 1992. Increased onset of sudden cardiac death in the first three hours after awakening. *Am J Cardiol*, 70:65-8.
97. Zandbergen AA, Baggen MG, Lamberts SW, Bootsma AH, de Zeeuw D, Ouwendijk RJ: Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. *Ann Intern Med* 2003; 139: 90–96.